Posts

Advances in immuno-oncology and adaptive cell therapy that began about a decade ago are enabling fresh, biology-driven approaches to bring therapeutic cancer vaccines closer to fruition.

DEM BioPharma, backed by an impressive list of investors, debuted Thursday with $70 million that will assist in its efforts to treat cancer with an approach that leverages CRISPR screening and macrophage biology in immuno-oncology.